Sentences with phrase «of pharmaceutical stocks»

It could have a dramatic impact on productivity, which in turn could have a major impact on the valuation of pharmaceutical stocks,» he said.

Not exact matches

A sobering example of this is anyone trying to profit from the pharmaceutical innovation with drug stocks.

In 2015, Ackman, the founder of hedge fund Pershing Square, announced his multi-billion dollar bet on Valeant Pharmaceuticals (vrx); he proceeded to lose nearly his entire investment, or $ 7.7 million every day for about two years, as Valeant stock sank 95 %.

Valeant Pharmaceuticals signage is displayed on a monitor on the floor of the New York Stock Exchange before the opening bell on March 21, 2016.

Papa's assurances lost some weight however when reports emerged two days later that the company was still under criminal investigation for potential insurance fraud related to its ties to specialty pharmaceutical Philidor — which erased all of the stock's recent gains.

Shares of beleaguered pharmaceutical Valeant jumped 10 % Wednesday after a team of Morgan Stanley analysts upgraded the stock.

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

After witnessing a 95 % decline in the pharmaceutical company's share price amid a series of scandals, Valeant's board, led by former shareholder and hedge fund manager Bill Ackman, smartly tied Papa's compensation to a recovery in the stock price.

As news emerges of Amazon considering a big push into pharmaceuticals, CNBC's Jim Cramer endorsed one of his favorite drugmakers, Celgene, after its stock fell off a cliff on Thursday.

Alnylam Pharmaceuticals stock plummeted 45 percent after the therapeutics company announced it was discontinuing its development of revusiran, a therapeutic aimed at treating hereditary ATTR amyloidosis.

Of course, other companies saw their stocks improve with the news, including pharmaceutical firms with Ebola vaccines such as Tekmira Pharmaceuticals (TKMR) and NewLink Genetics (NLNK), whose stocks soared.

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $ 7.50 per share.

Left, who has gained notoriety for successful bets against stocks such as Valeant Pharmaceuticals, explained that his rapid change of view on Twitter came as a result of the growing scrutiny surrounding social media and how companies handle users» personal information.

While exorbitant drug price hikes by Martin Shkreli's Turing Pharmaceuticals and Valeant have sparked outrage in Washington and tanked the stock prices of much of the pharmaceutical sector in the last six months, there's growing evidence that the controversy may be more smoke than fire.

HOUSTON, April 16, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.

Editor's note: An earlier version of this story said Teva Pharmaceuticals has proposed buying rival Mylan for $ 40 million in cash and stock.

Generic drugmaker Mylan has proposed buying Perrigo for about $ 29 billion in cash and stock in what would be the biggest pharmaceutical deal of the year so far.

Intercept Pharmaceuticals Announces Pricing of Upsized $ 250 Million Public Offering and Concurrent Private Placement of Common Stock

For Canadians, owning some of these stocks will not only provide income but also diversification, as there are few domestic pharmaceutical stocks to choose from.

One of those stocks is Actavis, the large - cap pharmaceutical company that has tripled in returns over the last three years.

Pharmaceuticals and biotech are heavily represented on the list of the top 15 stocks by 5 - year total return.

Allow me to direct you to Martin Shkreli, whom a Brooklyn jury convicted this month of security fraud related to a stock scheme involving a pharmaceutical company he co-founded, Retrophin.

It's no secret we've been on the opposite side of Bill Ackman's Pershing Square Capital on many recent stock picks, such as Herbalife (HLF), Mondelez (MDLZ), and, most notably, Valeant Pharmaceuticals (VRX).

John also sits on the Board of Strongco Corp, traded on the Toronto Stock Exchange as SQP and DelMar Pharmaceuticals, which is traded on OTCQX as DMPI.

In terms of valuation, Valeant Pharmaceuticals stock currently trades at TTM price to sales value of 0.58 x and price to book value of 1.40 x.

Biogen's (BIIB) expanded collaboration with Ionis Pharmaceuticals (IONS) to apply the latter's antisense technology to neurological diseases involved an upfront payment of $ 1 billion ($ 625 million purchase of common stock at a 25 % premium and $ 375 million upfront cash payment).

Following the Fed move, investors went straight for the glamour tech stocks, dumping utilities, pharmaceuticals, consumer staples, hospital stocks, insurance stocks - anything that smacked of safety or value.

Adamas Pharmaceuticals Inc (NASDAQ: ADMS), a small - cap pharmaceutical company that develops therapies to treat chronic neurologic disorders, is a «misunderstood» stock that has a potential upside of four times, Kerrisdale Capital said in a new report.

The last major takeover that Pfizer completed was the buyout of Wyeth Pharmaceuticals in 2009 for $ 68 billion in cash and stock.

One of my least favorite Health Care stocks is BioMarin Pharmaceuticals [s: BMRN], which gets my Very Dangerous rating.

We recently bought Alexion Pharmaceuticals ($ ALXN) in our Wagner Daily ETF and stock newsletter, and this post is an educational walk - through of the technical setup and subsequent trade management.

Yulia has a diverse experience of managing legal teams and projects in investments, telecommunication, metal production and pharmaceuticals, including corporations listed on NASDAQ, Hong Kong Stock exchange and Moscow Stock exchange.

He has also served as Delaware counsel for directors and board committees for such corporations as ABB, Ltd., Adelphia Communications Corporation, Airgas, Inc., Affiliated Computer Services, Inc., Alpha Natural Resources, Inc., AMF Holdings, Inc., Anheuser Busch Companies, Inc., Applied Materials, Inc., Ashworth, Inc., Bank of America Corporation, BarnesandNoble.com, Biosite, Inc., Cablevision Systems Corporation, Caterpillar, Inc., Citigroup, Inc., Clear Channel Outdoor Holdings, Inc., Coeur Mining, Inc., Computer Associates International, Inc., Cornerstone Therapeutics, Inc., Countrywide Financial Corporation, Countrywide Home Loans, Inc., Cysive, Inc., Danfoss A / S, Dreamworks Animation SKG, Duncan Energy Partners, E. I. du Pont de Nemours & Co., Inc., EON Labs, Inc., Epicor Software Corporation, Erickson Air Crane Inc., Fairfield Communities, Inc., FEDEX Corporation, First Franklin Financial Corporation, Fox & Hound Restaurant Group, FTI Consulting Inc., G.P. Strategies Inc., Gemstar International Group Ltd., Genencor International, Inc., Golden Telecom, Inc., Goldman Sachs, Google Inc., Health Management Associates, Inc., Hewlett - Packard Company, Hilton Worldwide Holdings, Inc., Houlihan's Restaurants, Inc., Huntsman Corporation, IGEN, Inc., ImClone Systems Incorporated, infoUSA, Inc., Insituform East, Inc., Intel Corporation, IntercontinentalExchange, Inc., iPass, Inc., Kenetech Corporation, Levi Strauss Associates, Inc., Liberty Media Corporation, Lifepoint Hospitals, Inc., Lorillard, Inc., Maytag Corporation, Micro General Corporation, Motorola, Inc., National Amusements, Inc. (majority stockholder of Viacom), National Steel Corporation, Net2Phone, News Corporation, NRG Energy, Inc., OEC Corporation, Online - City Search, Inc., PeopleSoft, Inc., Pharmacia Corporation, Phonefree.com, PLM International Inc., Printcafe Software, Inc., Pure Resources, Inc., Quest Software, Rent - A-Center, Inc., Rental Service Corporation, Republic Industries, Inc., Rockefeller Center Properties, Inc., Siliconix Incorporated, Simon Property Group Inc., Softbank Corp., Sotheby's, Space Imaging, Inc., Stock Building Supply Holdings, Inc., Suntory Holdings Limited, Take Two Interactive Software, Inc., Teppco Partners, L.P., The Hertz Corporation, The Talbots, Inc., Teva Pharmaceuticals USA, Inc., The Vanguard Group, Inc., The Walt Disney Company, TicketMaster, Todd A-O Corporation, Triad Hospitals, Inc., Unico Corporation, UTStarcom, Inc., Utz Quality Foods, Inc., Venoco, Inc., Veterinary Centers of America, Inc., VMWare, Inc., Walmart Stores, Inc., Walter Industries, Inc., Wheeling - Pittsburgh Corporation, Whistlepig, LLC, Wynn Resorts, Ltd., Zynga, Inc..

Most utilities, packaged food and mature pharmaceutical companies possess characteristics often thought of as typical for value stocks: high free cash generation, high quality balance sheets and high dividend payouts.

Now, in the IMS Health case, a big part of explaining why investors might take such a deal is that it offered a nice premium over the recent stock price and they might have been comparing IMS Health to pharmaceutical companies (IMS Health's customers) instead of pharmaceutical services companies (IMS Health's peers).

Recently, we did so with a swing trade in Onyx Pharmaceuticals ($ ONXX), which enabled us to score a 10 % gain on the price of the stock over just a 3 - day holding period.

Here is a chart of Merck, a pharmaceutical stock.

The iShares ETF is the largest covering the sector, tracking a set of biotechnology and pharmaceutical stocks that trade on the Nasdaq stock market.

With almost 200 stocks in its portfolio, the iShares ETF claims about 80 % of its assets are invested in biotechnology specifically, with the remaining 20 % split between pharmaceutical companies and businesses specializing in tools and services for the life sciences industry.

No. 3: The year of big pharma In the past five years, big cap pharmaceutical stocks have lagged biotech stocks because they've struggled to fill revenue gaps created by the patent cliff.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

Some examples of defensive sectors include utility, pipeline, pharmaceutical stocks as well as stocks with high dividend payouts.

Because of the unique requirements for bringing products to market, pharmaceutical industry stocks are best analyzed by using certain key financial ratios.

For example, I'm considering buying funds invested in the Biotech, Software / IT, Retailing, Pharmaceuticals, and Chemicals sectors of the market, which have outperformed the typical 7 % average annual return of a typical «all stocks all sectors» portfolio.

If a pharmaceutical company loses any of its drug manufacturing right / permission because of a regulatory effect, then it will definitely affect the company's profit and hence, the stock price.

The U.S. market in particular offers a wealth of sectors that are minimal or non-existent in Canada: high - tech, pharmaceuticals and bio-tech, defence stocks, social media stocks and many more.

These are the funds / schemes which invest in the securities of only those sectors or industries as specified in the offer documents, e.g., Pharmaceuticals, Software, Fast Moving Consumer Goods (FMCG), Petroleum stocks, Information Technology (IT), Banks, etc..

Back when the Canadian dollar was trading roughly at par with the U.S. dollar (and briefly above it), it was a great opportunity for Canadian investors to diversify outside of the Canadian equity market to buy world - class U.S. stocks in sectors underrepresented in Canada: technology, health care, pharmaceuticals, consumer staples and the like.

Following the Fed move, investors went straight for the glamour tech stocks, dumping utilities, pharmaceuticals, consumer staples, hospital stocks, insurance stocks - anything that smacked of safety or value.

Sequoia staked its fate to the performance of Valeant Pharmaceuticals, a firm adored by hedge fund managers and Sequoia — which plowed over a third of its portfolio into the stock — for its singular strategy: buy small drug companies with successful niche medicines, then skyrocket the price of those drugs.